Bezafibrate is a second generation fibric acid derivative and is used to lower cholesterol levels. It is an alternative for gemfibrozil in mixed hyperlipidaemias (type III, IV and V). Though it has also been indicated in hypercholesterolaemia (type II), it is inferior to statins and resins. Bezafibrate has not shown propensity to increase LDL-CH in hypertriglyceridaemic patients and appears to have greater LDL-CH lowering action than gemfibrozil. Decreased level of circulating fibrinogen and glucose has been demonstrated. The 5 year Bezafibrate Coronary Atherosclerosis intervention Trial (BECAIT) in young male post MI subjects has shown it to slow atherosclerotic process and reduce coronary events. Bezafibrate Coronary Atherosclerosis intervention Trial was a study that demonstrated the efficacy of the drug in patients with coronary disease.
Bezafibrate Side effects:
Adverse effects and contraindications of bezafibrate are similar to other fibrates. Main side effects are g.i. upset, myalgia, rashes. Dose reduction is needed in elderly and in renal insufficiency to prevent overdosage. Action of oral anticoagulants may be enhanced.
In contrast to other fibrates, combination of bezafibrate with a statin has not so far been found to increase the incidence of rhabdomyolysis.
Dose: 200 mg TDS with meals. BEZALIP 200, 400 mg tab.